*Read Disclaimer Sponsored Content
{{current_date_full}} | Unsubscribe
Hello!
We wanted to give you a quick intraday update on our new alert, VolitionRx Limited (NYSE American: VNRX).
Following our alert this morning, VNRX opened at 1.44 and has so far rallied to a high of 1.56 (+8%).
This could be just the start of a much bigger opportunity unfolding.
The 20-day moving average of 2.14 is +48% above today's open.
Beyond that, the 50-day moving average sits at 2.54, +76% upside from today's open.
Wall Street is starting to pay attention to VNRX - and for good reason.
This could be a very important turning point for the company.
Here are some of the company’s recent accomplishments as explained in the May 27, 2026 press release:
Capture-Seq™ Breakthrough in Cancer Detection.
“We were delighted to submit for peer review a manuscript entitled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy". This paper showcases both a new method, Capture-Seq™, and new biomarkers for the detection of cancer, holding the promise of accurate, low-cost tests for a wide range of cancers.”
“We also announced over 95% sensitivity for stage I & II cancers with 95% specificity in a blinded validation cohort2. For patients, the potential significance is huge. If validated in larger cohorts, CTCF Capture-Seq™ could contribute to Multi-Cancer Early Detection (MCED) fulfilling a significant unmet clinical need.”
“This scientific breakthrough has generated a lot of interest with potential licensing partners. We believe that this technology could, with further development, become very widely used and we are actively advancing structured discussions with potential commercial partners to accelerate the integration and launch of this technology as soon as possible. We are delighted to have grown the commercial interest in the first quarter, with an increase in discussions, including technical evaluations.”
“We believe MCED represents a significant commercial opportunity with Total Addressable Markets on an annualized basis of approximately $23 billion and a potential additional $13 billion should it also prove useful in the detection of Minimal Residual Disease”
Companion Animal Health: Nu.Q® Vet Feline Milestone
“We announced the submission of a clinical manuscript3 reporting the high accuracy of our Nu.Q® Vet Feline prototype assay in detecting lymphoma in cats, the most common cancer in the species4. At 97% specificity the assay detected 86% of feline lymphomas3 . This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in veterinary medicine.”
This represents a tremendous commercial opportunity for Volition:
“The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment.
We will also generate ongoing revenue, in this large and growing market where our technology meets an unmet need.
The Nu.Q® Vet Canine test is already available in more than 20 countries, and we believe the addition of a feline equivalent could potentially double our total addressable market in the companion animal space1.”
Sepsis & NETosis Validation
“The inclusion of our Nu.Q® NETs assay in a real-world interventional evaluation of early detection of sepsis, in a government-backed (~$7.3 million) program in France remains on track to start in the third quarter of 2026. The DETECSEPS program provides an opportunity to receive individualized or personalized care, adjusted to the risk of deterioration and progression to sepsis.”
“We reported two new, potentially large, clinical use cases for our Nu.Q® NETs assay beyond sepsis. In conjunction with the Mayo Clinic5, we demonstrated Nu.Q® NETs' potential clinical utility in aiding early risk identification which could inform targeted preventive strategies in acute trauma care. We also demonstrated potential use for patient management of a chronic disease, Hidradenitis Suppurativa,6 which affects about 1% of the world's population7. Both use cases have the potential to be large markets.”
Breakthrough Finger-Prick Detection of Nucleosomes
“We also announced a major technical milestone with the successful detection of nucleosomes in capillary blood from critically ill sepsis patients using our lateral flow prototype. This finger prick sample test could be used at the bedside, in the ER, or even at home in a self-test lateral flow kit, similar to COVID-19 or pregnancy testing, thereby greatly expanding the potential market beyond centralized lab testing.”
“With recent estimates indicating approximately 166 million cases of sepsis worldwide the addressable market is huge. All-cause sepsis related deaths in 2021 represented 31.5%8 of total global deaths, with the highest burden of mortality in lower-middle-income countries.”
Lung Cancer Reimbursement Submission
“In the fourth quarter of 2025, we received our first order for the Nu.Q® Cancer assays for clinical certification ahead of routine clinical use in lung cancer and in January were delighted to announce that preparation of the reimbursement submission is underway, actively supported by the Hospices Civils de Lyon (HCL), France's second largest university hospital system. Reimbursement will be a major milestone for Volition in the commercialization and licensing of Nu.Q® in the human cancer field. Once achieved, we anticipate the introduction into routine clinical use in France by the end of 2026.”
More recently, on June 3rd the company announced:
“VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring”
“Ebola is a rare but severe illness in humans, with an average case fatality rate around 50%1 . The disease is characterized by a low white cell count, disseminated intravascular coagulation, immunosuppression and septic shock.”
“The ongoing Ebola outbreaks across Sub-Saharan Africa highlight a persistent medical challenge: because initial symptoms are non-specific, clinicians in remote field facilities cannot easily identify infected patients sufficiently early to prevent disease spread and for early treatment.”
A Call for Strategic Partnerships
“With its core laboratory automated assays already CE-Marked and in use in a number of clinical programs, Volition is looking to translate this technology into immediate field application. The company is actively inviting global health organizations, pharmaceutical developers, non-governmental organizations (NGOs), and distribution partners to collaborate on field trials, manufacturing scale-up, and potential deployment of its LFT prototypes in outbreak zones.”
Mr. Remi Rabeuf, VP of Corporate Alliances and Strategic Partnerships, Volition said:
"Our Nu.Q® technology has demonstrated its potential to improve sepsis care in advanced Western settings and with this new patent filing and our successful finger-prick LFT prototype, we now hope to take this prognostic power into most low- and middle-income country healthcare settings.
"We are seeking the right institutional and commercial partners to help us get this low-cost, life-saving triage tool into the hands of frontline healthcare workers fighting Ebola."
In addition, last week, the company announced:
“VolitionRx Announces Pricing of $4.6 Million Public Offering”
“$4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrants”
“The offering is expected to close on June 9, 2026, subject to the satisfaction of customary closing conditions.”
We are continuing to monitor VNRX for a sustainable breakout opportunity.
Sources: S, WHO, Cancer, Presentation, PR1, PR2, PR3, PR4, PR5, PR6, PR7, PR8, PR9, PR10, PR11, PR12, PR13, PR14, PR15, PR16, PR17, Website, Chart
Happy Trading!
SmallCapStocks Team
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
DISCLAIMER:
You should read and understand this disclaimer in its entirety before joining the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.
Owners and operators of the Publisher expect to be compensated eight thousand dollars by bank wire transfer on 6/16/26 for the distribution of this advertisement about VNRX dated 6/16/26. Previously, owners and operators of the Publisher have been compensated eight thousand dollars by bank wire transfer on 5/12/26 for the distribution of a prior advertisement about VNRX. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.
You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at [email protected] to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link:
www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.